← Back to Search

Episodic Future Thinking for Type 2 Diabetes

N/A

Recruiting

Led By Jeffrey Stein, PhD

Research Sponsored by Virginia Polytechnic Institute and State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Not ambulatory

Intellectual impairment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 24

Awards & highlights

No Placebo-Only Group

Summary

This trial will compare the effects of episodic future thinking (EFT) on delaying discounting in adults with type 2 diabetes.

Who is the study for?

This trial is for adults with type 2 diabetes who live in urban or rural areas, have an HbA1c level of at least 7.7%, and a body mass index (BMI) of 30 or higher. It's not suitable for those with intellectual impairments, gestational diabetes, pregnant or lactating women, non-ambulatory individuals, or unmanaged psychiatric conditions.

What is being tested?

The study tests if 'Episodic Future Thinking'—imagining future events to influence present decisions—can help manage type 2 diabetes better than 'Healthy Information Thinking'. Participants are randomly assigned to one of these two groups and followed over a period of 24 weeks.

What are the potential side effects?

Since the interventions involve psychological strategies rather than medications, traditional side effects like you'd see with drugs aren't expected. However, participants may experience emotional discomfort when engaging in these thinking exercises.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot walk on my own.

Select...

I have an intellectual disability.

Select...

I do not have any untreated mental health conditions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 24

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 24

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in body mass index from baseline (Week 0) to Week 24

Change in body mass index from baseline (Week 0) to Week 8

Change in glycemic control from baseline (Week 0) to Week 24

+1 more

Secondary study objectives

Change in dietary intake from baseline (Week 0) to Week 24

Change in dietary intake from baseline (Week 0) to Week 8

Change in physical activity from baseline (Week 0) to Week 24

+4 more

Other study objectives

Change in delay discounting from baseline (Week 0) to Week 24

Change in delay discounting from baseline (Week 0) to Week 8

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Episodic Future ThinkingExperimental Treatment1 Intervention

Participants will generate vivid, episodic events and be prompted via a guided smartphone app to engage in EFT in their daily lives. EFT will be paired with diet and physical activity support.

Group II: Healthy Information ThinkingActive Control1 Intervention

Participants will be prompted via a guided smartphone app to thinking about their written responses to informational health vignettes during their daily lives. The HIT condition will be paired with diet and physical activity support.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Episodic Future Thinking

2018

N/A

~460

0 / 3Eligibility criteria met